RxDoctor Payments Data

Sarala Ghanapuram, MD

Internal Medicine · Lincoln, CANPI 1093079782

Payments from drug & device makers

$2,410in general payments, 2019–2025

Across 113 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$297
  • AbbVie$269
  • Boehringer Ingelheim$248
  • Astellas Pharma US Inc$221
  • GSK$134
  • Exact Sciences$126
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$2,25494%
  • Education$1566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,410 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$233,144
Medicare patients
404
Services billed
2,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$55,824
OzempicSemaglutide34$47,563
EliquisApixaban33$47,260
FarxigaDapagliflozin Propanediol25$33,993
JanuviaSitagliptin Phosphate25$33,322
Xtampza ErOxycodone Myristate12$28,521
LinzessLinaclotide16$17,125
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$13,227
Spiriva HandihalerTiotropium Bromide16$9,860
CreonLipase/Protease/Amylase15$8,290
SymbicortBudesonide/Formoterol Fumarate13$7,628
PremarinEstrogens, Conjugated11$7,287
Tresiba Flextouch U-100Insulin Degludec16$5,368
Levothyroxine Sodium378$5,094
Atorvastatin Calcium424$4,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin, Paxlovid$99$55,97760 claims
Boehringer IngelheimJardiance$248$55,82446 claims
Novo NordiskOzempic$113$47,56334 claims
AstraZenecaFarxiga, Symbicort$297$41,62138 claims
AbbVieLinzess, Creon, Synthroid$269$28,08568 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Lincoln

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →